Oral Cancer News

New tool helps dentists detect oral cancer

Source: www.nbcdfw.com Author: Ashante Blaize Nationwide, an average of one person dies every hour from oral cancer, which is called a silent killer because it is difficult to detect and advances quickly, a Plano dentist said. Just two short months ago, Janet Kiser's relationship with her dentist, Dr. Frank Rabinowitz, changed. He's now more than just a D.D.S. to Kiser. After he detected a tumor growing inside the roof of her mouth, Kiser calls him a lifesaver. "The description of people who would typically have that kind of tumor was someone who chewed tobacco, or smoked a pipe, or at least smoked something," said Kiser. Kiser said she didn't do any of those things. The fear was she could have oral cancer. "Its a very invasive cancer. It's very fast growing and it's not always looked for," said Rabinowitz. Thanks to a new device called VELscope, Rabinowitz was able to take a more in depth look at Kiser's growth. "We got it and then we called Janet and asked her to come in, if I could look at her growth in her mouth with the VELscope," said Rabinowitz. "We are looking for tissues that may have changed." After using the device's ultraviolet light, Rabinowitz was able to pin point the size and growth of the tumor, take a picture of it, and send it to the oral surgeon who would remove Kiser's tumor. "The surgeon told me that he could actually see better margins and determine how much of the [...]

Oral Cancer Foundation News Team - A2009-09-27T11:30:22-07:00September, 2009|Oral Cancer News|

37% of U.S. teen girls got HPV vaccine

Source: www.medscape.com Author: Daniel J. DeNoon More than one in three U.S. teen girls has had at least one shot of Gardasil, a CDC survey shows, but only 18% of girls got the three shots needed for protection. The survey includes girls vaccinated through 2008, two years after Gardasil's approval. A second HPV vaccine, GlaxoSmithKline's Cervarix, is expected to be approved this year. Gardasil, from Merck, protects against the four strains of the sexually transmitted human papillomavirus (HPV) that cause most cases of cervical cancer and genital warts. But other HPV strains also cause these diseases, so even vaccinated women still need regular Pap exams. Gardasil's acceptance varied widely by state. More than half of all teen girls aged 13 to 17 had at least one shot of the HPV vaccine in six states: Arizona, Massachusetts, New Hampshire, New York, Rhode Island, and Vermont. Fewer than one in five girls got the vaccine in three states: Georgia, Mississippi, and South Carolina. Coverage was highest in Rhode Island (54.7%) and New Hampshire (54.4%) and lowest in Mississippi (15.8%) and Georgia (18.5%). Cervical cancer is more common in women of Hispanic descent and in people living below the poverty level. Perhaps because the Vaccines for Children (VFC) program provides the expensive vaccine to uninsured children, girls in these groups had higher rates of coverage than other girls. The CDC reported results of the survey in today's issue of Morbidity and Mortality Weekly Report. Source: MMWR, Sept. 17, 2009; vol 58: pp 997-1001.

Oral Cancer Foundation News Team - A2009-09-25T12:57:21-07:00September, 2009|Oral Cancer News|

Port Coquitlam dentist hopes to save a life with a Velscope

Source: www.bclocalnews.com Author: Diane Strandberg A Port Coquitlam dentist is offering to do more than fix cavities and polish teeth. Dr. Glenn Keryluk wants to save a life. He's purchased an oral cancer screening device he expects will shortly become standard equipment in all dentist offices and he is offering to screen patients referred to by local doctors. "It's the latest and greatest in cancer detection," Keryluk says of the Velscope, a hand-held device that shines a blue light on oral lesions that could be cancerous. Manufactured by a White Rock-based company, the Velscope can show abnormal tissue below the surface, even before it becomes apparent to the clinicians' eye. Healthy tissue glows green under the light but cancerous tissue looks black. Being able to detect oral cancer early is key to surviving the disease because the longer the cancer is around the more likely it will spread to nearby organs. Keryluk held a free screening day for patients at his office at 2099 Lougheed Highway recently and is cutting standard fees for the procedure or waving them entirely for people without dental coverage. The procedure is painless, takes only a few minutes and a photograph of the lesion taken by the machine can be sent to a physician for follow-up. "If you catch it early it could be that a person's life is saved. I just want people to be aware of the technology out there," Keryluk said. He's only seen two cases of oral cancer in 20 years [...]

Oral Cancer Foundation News Team - A2009-09-25T12:36:26-07:00September, 2009|Oral Cancer News|

Identification of highly radiosensitive patients may lead to side effect-free radiotherapy

Source: www.ecancermedicalscience.com Author: staff An international group of scientists has taken the first step on the road to targeting radiotherapy dosage to individual patients by means of their genetic characteristics, a radiation oncologist told Europe’s largest cancer congress, ECCO 15 – ESMO 34, in Berlin today. Professor Dirk de Ruysscher, from Maastricht University Medical Centre, Maastricht, The Netherlands, said that his team’s work might provide the basis for personalised radiotherapy in which, with a simple blood test, doctors may be able to select the optimal radiation dose for a particular patient. The team of scientists from The Netherlands, Belgium, Germany, and Canada studied a group of patients with hypersensitivity to radiation therapy, drawn from the largest world-wide database available – the European Union-funded Genetic pathways for the prediction of the effect of irradiation (GENEPI) study, which integrates biological material with patient data and treatment specifications. The database included information from more than 8000 European patients. “Part of this project is the establishment of a sub-database in which very rare patient characteristics are brought together with the hypothesis that their genetic traits will enable the characterisation of molecular pathways related to radio-sensitivity,” explained Professor de Ruysscher. “A major problem for radiation oncologists at present is that we are bound by the need to avoid damage to normal tissues. This means that the dose of radiation generally used is governed by the response of the most radiosensitive patients, and this may lead to many patients receiving lower than optimal doses, hence affecting [...]

Oral Cancer Foundation News Team - A2009-09-25T07:51:01-07:00September, 2009|Oral Cancer News|

Induction with Docetaxel, Cisplatin, and 5-FU provides survival benefits beyond 5 years in head and neck cancer

Source: www.docguide.com/news Author: Chris Berrie Induction with docetaxel, cisplatin, and 5-fluorouracil (5-FU) provides sustained significant survival advantages beyond 5 years compared with cisplatin and 5-FU in patients with locally advanced squamous cell cancer of the head and neck. Jochen Lorch, MD, Head and Neck Oncology Programme, Dana Farber Cancer Institute, Harvard University, Boston, Massachusetts, presented a 5-year follow-up analysis of the multicentre, randomised, open-label, phase 3 Cisplatin and Fluorouracil Alone or With Docetaxel in Head and Neck Cancer (TAX 324) at the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO). The benefits of docetaxel in combination with cisplatin and 5-fluorouracil (TPF) was shown in the original TAX 324 and TAX 323 studies. Results of the follow-up were presented here on September 22. TAX 324 included 501 patients with measurable, nonmetastatic stages III and IV squamous cell carcinoma of the head and neck, with a primary tumour location in the oral cavity, oropharynx, larynx or hypopharynx, and unresectable disease. A World Health Organization (WHO) performance status (PS) of 0/1 and no prior chemotherapy or radiotherapy were also specified. Patients were randomised to induction therapy of TPF (n = 255) or cisplatin plus 5-fluorouracil (PF) on days 1 to 4, every 3 weeks for 3 cycles (n = 246). The induction treatments were followed by chemoradiotherapy with carboplatin area under the curve (AUC) 1.5, weekly and daily radiotherapy (5 days/week). In the original study, there was a significant 13% improvement [...]

Oral Cancer Foundation News Team - A2009-09-25T04:48:30-07:00September, 2009|Oral Cancer News|

For Apple, accessibility is much more than lip service

Source: arstechnica.com/apple/news Author: Chris Foresman We have discussed the advancements Apple has made in accessibility to Mac OS X and even the iPhone in the past, but recent examples show that Apple's attention to detail in technologies technologies like VoiceOver and Voice Control can make all the difference in the world for users with speech or sight impairments. These technologies are earning Apple awards and the appreciation of users and further separate Apple from the competition. It was just a few weeks ago when we noted comments from industrial designer Mike Calvo, whose company Serotek is involved in accessibility design, on how well accessibility is engineered into the iPhone. "Apple understands that accessibility should be about far more than developing custom solutions which pay lip service to the idea of accessibility but detract from the out-of-box experience enjoyed by everyone else," he wrote in his assessment of the iPhone. Now, after the release of iPhone OS 3.1, the Mac-cessibility Network noted that Apple has added an additional 16 improvements to the accessibility features of Apple's mobile devices. These include controls for cutting and pasting text or even editing video using VoiceOver and Voice Control, reading PDF files, and using Voice Control over a Bluetooth headset. The continued attention to detail shows that Apple doesn't take accessibility lightly. This attention to detail has also earned Apple an award from the National Federation for the Blind. Tomorrow, during its first ever Web Accessibility Day conference, the NFB will give an award to [...]

Oral Cancer Foundation News Team - A2009-09-24T16:52:46-07:00September, 2009|Oral Cancer News|

Initial COIN study results presented at European Oncology Congress

Source: Drugs.com Author: Staff • Results inconsistent with data from all Erbitux pivotal studies • Further analyses planned by the Medical Research Council that conducted the independent COIN study Berlin/Darmstadt, Germany, September 23, 2009 – The Medical Research Council (MRC), a UK-based, publicly-funded organization dedicated to improving human health, today presented the initial results of the independent Phase III COINa study, which did not meet its primary endpoint of overall survival (OS).1 These findings were presented today at the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO) in Berlin, Germany. The COIN study was designed to evaluate whether the addition of Erbitux® (cetuximab) to one of two oxaliplatin-based chemotherapy regimens significantly improved outcomes in previously untreated metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors. The median OS was not statistically significant at 17.0 months in the Erbitux treatment arm compared to 17.9 months for the chemotherapy-alone group (hazard ratio [HR] 1.038; p=0.68).1 “Imbalances in the chemotherapy administered between the different study arms were reported previously in the interim safety analysis,” explained Dr. Wolfgang Wein, Executive Vice President, Oncology, Merck Serono, a division of Merck KGaA, Darmstadt, Germany. “Further analysis of the dose intensity and 2nd-line treatment, and other factors, such as the advanced disease of patients in the study, are ongoing to determine why the COIN results are not aligned with existing evidence from the other randomized, 1st-line studies, including the significant increase in overall survival achieved with the CRYSTAL study.” Results [...]

Charlotte Parker2009-09-24T16:48:29-07:00September, 2009|Oral Cancer News|

A different camel is back in the glossies

Source: nytimes.com Author: Andrew Adam Newman The two largest tobacco companies in the United States voluntarily stopped advertising cigarettes in magazines, with Philip Morris, whose brands include Marlboro, ceasing in 2005 and R. J. Reynolds, whose brands include Camel, at the beginning of 2008. Now the Camel logo is back prominently in major glossies, including Rolling Stone, Sports Illustrated and Maxim — but not to advertise cigarettes. R. J. Reynolds is advertising Camel Snus, a tobacco packet that wedges in the upper lip and, unlike chewing tobacco, is promoted as “spitless” because low salt content spares users the unpleasantness of public expectoration. Although snus is popular in Sweden, this is the first time it has been marketed in the United States by a major American tobacco company. The campaign, by Quaker City Mercantile in Philadelphia, pitches Camel Snus (pronounced snoose) as a way around smoking bans. The ads cater to specific magazine audiences, with a recent issue of Rolling Stone promoting snus as “sweaty outdoor festival friendly” and one in Sports Illustrated declaring it “extra inning friendly.” Others call snus “your flight just got canceled friendly,” “ridiculously long conference call friendly” and “fancy hotel friendly.” David Howard, an R. J. Reynolds spokesman, said that the company had not reversed its magazine policy, but that this was a Camel of another color. “We do not advertise cigarettes in print right now and have not done that for a couple years, but Camel Snus is not a cigarette,” Mr. Howard said. “This [...]

Oral Cancer Foundation News Team - A2009-09-23T13:54:31-07:00September, 2009|Oral Cancer News|

Charting the path from infection to cancer

Source: www.cancer.gov/ncicancerbulletin Author: Eleanor Mayfield Few people associate infection with cancer, but close to one-fifth of all cancers in the world are caused by infectious agents, including viruses, bacteria, and other microbes. In developing countries, the number is higher—about one in four—while in industrialized countries, such as the United States, it is about one in 12. Infectious agents that can cause cancer are extremely common, infecting millions of people around the world. Yet it is rare and takes a long time for an infection to develop into cancer. “You need a lot of things to happen, or not happen, to get from an infection to cancer,” said Dr. Douglas R. Lowy, chief of NCI’s Laboratory of Cellular Oncology and a leader in the molecular biology of tumor viruses. The microbes responsible for most of the global burden of infection-associated cancer are: the bacterium Helicobacter pylori, which causes gastric cancer; cancer-causing strains of the human papillomavirus (HPV), which cause cervical cancer and other cancers; and the hepatitis B and C viruses, which cause liver cancer. These four microbes alone cause more than 15 percent of all cancers worldwide. Other cancers known to be associated with infectious agents include leukemia and lymphoma; anal, penile, vaginal, and vulvar cancer; and tongue and throat cancers. Last week, researchers reported new evidence linking aggressive prostate tumors to a virus. Role of the Immune System Microbes can lead to cancer by a variety of mechanisms that are not yet fully understood, explained Dr. Allan Hildesheim, chief [...]

Oral Cancer Foundation News Team - A2009-09-23T08:59:07-07:00September, 2009|Oral Cancer News|

Flavored cigarette ban takes effect 9/22

Source: MSN.com Author: Karen Pallarito New federal law may help deter young smokers, health advocates say TUESDAY, Sept. 22 (HealthDay News) -- Young people who enjoy a hint of vanilla, berry or chocolate when they light up are about to have their favorite smokes snuffed out. A new federal law banning fruit- and candy-flavored cigarettes takes effect Sept. 22. The prohibition is part of the Family Smoking Prevention and Tobacco Control Act, legislation that grants the U.S. Food and Drug Administration the authority to regulate tobacco products. President Barack Obama signed the measure into law June 22. Studies show that flavored cigarettes, which have been around for about a decade, disproportionately appeal to America's youth. Thus, banning the manufacture and sale of kid-friendly flavored cigarettes is a critical step toward deterring young smokers, health advocates said. "Almost 90 percent of adult smokers start smoking as teenagers. These flavored cigarettes are a gateway for many children and young adults to become regular smokers," FDA Commissioner Dr. Margaret A. Hamburg said in a news release. "The FDA will utilize regulatory authority to reduce the burden of illness and death caused by tobacco products to enhance our nation's public health." Gregg Haifley, associate director of federal relations for the American Cancer Society Cancer Action Network in Washington, D.C., said, "Banning candy and fruit flavorings in cigarettes can have a significant effect on the reduction of initiation of smoking among youth, as well as reducing the number of youth who go on to regular, [...]

Charlotte Parker2009-09-22T16:48:58-07:00September, 2009|Oral Cancer News|